Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : Unit Seeks US Nod For Xarelto to Treat Blood Clots in Pediatric Patients

06/23/2021 | 11:19am EDT


© MT Newswires 2021
All news about JOHNSON & JOHNSON
12:10pCORONAVIRUS- SOUTH AFRICA : SA Ramps Up COVID-19 Inoculation The department will..
AQ
07/30J&J Won't Be Held Liable For Illinois Woman's Death in Talc Case -- Reuters
DJ
07/30JOHNSON & JOHNSON : Janssen Wins US FDA Approval for Intravenous Uptravi in Pulm..
MT
07/30UPTRAVI® Receives FDA Approval for Intravenous Use in Adult Patients with Pul..
CI
07/30States race to use COVID-19 vaccines before they expire
AQ
07/29JOHNSON & JOHNSON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
07/29EMERGENT BIOSOLUTIONS : resumes COVID-19 vaccine production
AQ
07/29JOHNSON & JOHNSON : SA to Soon Administer Over 300,000 Covid-19 Vaccines a Day
AQ
07/29JOHNSON & JOHNSON : Women Cancer Victims Opposed to Johnson & Johnson's 'Texas T..
PR
07/29JOHNSON & JOHNSON : and Vaccine Gets Approval
AQ
More news
Financials (USD)
Sales 2021 94 452 M - -
Net income 2021 22 808 M - -
Net Debt 2021 853 M - -
P/E ratio 2021 20,2x
Yield 2021 2,41%
Capitalization 453 B 453 B -
EV / Sales 2021 4,81x
EV / Sales 2022 4,59x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 172,20 $
Average target price 184,35 $
Spread / Average Target 7,06%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.16.30%239 637
NOVARTIS AG0.28%225 343
ELI LILLY AND COMPANY44.22%221 348
NOVO NORDISK A/S35.94%212 048